A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Keri P Mattox Is Appointed Chief Communications and Administration Officer of Zimmer Biomet

What To Know

  • “As we continue to focus on delivering on our mission to alleviate pain and improve the quality of life for people around the world, it’s essential to create a  function responsible for building and executing a comprehensive strategy around Environmental, Social and Governance (ESG) initiatives,”.
  • Keri P Mattox previously served as Senior Vice President, Investor Relations and Chief Communications Officer, and now adds responsibility for building and executing a comprehensive strategy around Environmental, Social and Governance (ESG) initiatives and increasing CEO visibility, engagement and accessibility to her portfolio.

Keri P Mattox will report to the President, Chief Executive Officer and Chairman Bryan Hanson.

Keri P Mattox previously served as Senior Vice President, Investor Relations and Chief Communications Officer, and now adds responsibility for building and executing a comprehensive strategy around Environmental, Social and Governance (ESG) initiatives and increasing CEO visibility, engagement and accessibility to her portfolio.

“As we continue to focus on delivering on our mission to alleviate pain and improve the quality of life for people around the world, it’s essential to create a  function responsible for building and executing a comprehensive strategy around Environmental, Social and Governance (ESG) initiatives,” said Mr. Hanson. “Since joining Zimmer Biomet in January 2020, Keri has spearheaded our brand evolution, worked to build a best-in-class communications and IR function and expanded and publicly launched the Zimmer Biomet Foundation, overseeing the creation of our Team Member Relief Fund, Giving Center and local and global philanthropy activities. I am confident that in this expanded role, Keri will continue to raise ZB awareness and I look forward to partnering more closely with her as part of our ongoing evolution and transformation.”

Kerri P Mattox was appointed Senior Vice President, Investor Relations and Chief Communications Officer in January 2020, responsible for strategically integrating, aligning and driving investor relations, communications and philanthropy functions and activities. Prior to joining Zimmer Biomet, she served as Global Lead, Integrated Corporate Communications at W2O Group (now Real Chemistry), an international healthcare-focused marketing and communications firm. There she was responsible for strategically shaping and expanding the firm’s global corporate communications, investor relations, crisis communications, M&A, board engagement and corporate social responsibility/foundation capabilities and offering.

Prior to W2O, Ms. Mattox was Vice President, Corporate & Investor Relations at AmerisourceBergen, a healthcare company ranked #10 on the Fortune 500. She also held executive leadership team level positions at Endo International and Auxilium Pharmaceuticals and spent more than 10 years at communications agencies in leadership positions. Earlier in her career, Ms. Mattox was a reporter with Hearst Newspapers. She holds a B.A. from Boston University and an M.A. in Journalism from the University of Maryland.

Other Executives In the News

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Executives on the Move

“Adding Michael to the Avation leadership team is our next step in launching Vivally,” said Jill Schiaparelli, founder and CEO of Avation Medical. “Patients have been crystal clear that they want a surgical-free, non-invasive treatment option for their OAB symptoms. Our focus now is to ensure that Vivally is easily accessible to the 46 million patients suffering from OAB in this country.”
Dennis has an extraordinary depth of knowledge and is highly respected in the obesity field; I could not imagine anyone more perfect to lead our company,” said Jeff Arnold, Chairman and a Director at Xeno Biosciences since 2017.
Peter Eckes offers more than a 30-year career in the agricultural industry, and provides a unique appreciation for what it takes to bring innovation to the modern agriculture marketplace at scale without losing sight of farmer and consumer needs.

By using this website you agree to accept Medical Device News Magazine Privacy Policy